



Department
of Health &
Social Care

2014 Pharmaceutical Price Regulation Scheme (PPRS) and The Branded Health Service Medicines (Costs) Regulations 2018

**Aggregate net sales and payment information 19
October 2020**

Published November 2020

Contents

Contents	1
Aggregate Net Sales and Payment Information — 19 October 2020.....	2
TABLE 1 — Audited annual PPRS Payment Sales Reports: measured spend in growth calculation by calendar year	2
TABLE 2 — PPRS payment sales reports: net sales covered by the PPRS payment and resulting PPRS payments.....	3
TABLE 3 — Statutory scheme sales reports: net sales covered by the statutory scheme payment and resulting payments.....	5
General notes	6

Aggregate Net Sales and Payment Information — 19 October 2020

TABLE 1 — Audited annual PPRS Payment Sales Reports: measured spend in growth calculation by calendar year

Aggregate Net Sales Subject to Medicines Bill Growth Calculation (Measured Spend)

	2013/2014	2014/2015	2015/2016	2016/2017	2017/2018
2013	£7,834M	N/A	N/A	N/A	N/A
2014	£8,326M	£8,092M	N/A	N/A	N/A
2015	N/A	£8,141M	£8,287M	N/A	N/A
2016	N/A	N/A	£8,558M	£8,557M	N/A
2017	N/A	N/A	N/A	£9,007M	£8,638M
2018	N/A	N/A	N/A	N/A	£8,910M

Table 1 notes

1. Table 1 sets out aggregate information for calendar years 2013, 2014, 2015, 2016, 2017 and 2018 reported through 2014 PPRS members' audited annual PPRS Payment Sales Reports or best available information where the audited submissions have yet to be provided.
2. The information set out is the net sales subject to branded medicines bill growth calculation (measured spend).
3. Measured spend is defined in paragraph 6.6 of the PPRS and means the spend which is controlled by the PPRS Payments mechanism. It includes sales of new products.

Each column of the table contains a separate basket of companies for each growth calculation, which are dependent on the members of the scheme included in the growth

calculation and ensuring that the same companies are in both the numerator and the denominator of the respective calculations.

The figures in all parts of Table 1 do not take into account the treatment of the Cancer Drugs Fund (CDF) in the growth calculation following the agreement reached on the CDF between the Department and the ABPI. The effect of this is that the excluded amounts are added to the Allowed Spend. The amount (net of VAT) added to Allowed Spend following the CDF agreement is:

- Calendar year 2014 — £ 91M
- Calendar year 2015 — £107M
- Calendar year 2016 — £ 35M
- Calendar year 2017 — £ 28M

The addition to the allowed spend follows the method set out in the revised [addendum to the PPRS](#). The figures for 2014, 2015, 2016 and 2017 are final.

TABLE 2 — PPRS payment sales reports: net sales covered by the PPRS payment and resulting PPRS payments

Period	Aggregate net sales covered by the PPRS payment Column 1	Resulting aggregate PPRS payments Column 2
2013	£7,901M	N/A
2014	£8,337M	£311M
2015	£8,178M	£846M
2016	£8,069M	£629M
2017	£8,163M	£387M
2018	£7,903M	£616M

Table 2 notes

1. Table 2, which is derived from audited annual PPRS Payment Sales Reports and unaudited quarterly PPRS Payment Sales Reports provided by members of the 2014 PPRS, sets out aggregate annual audited information showing net sales covered by the PPRS Payment and the resulting PPRS Payments for the following periods:

Audited
2013
2014
2015
2016
2017
2018

There are two columns of information:

Column 1 — Aggregate net sales covered by the PPRS payment;

Column 2 — Resulting aggregate PPRS payments due for the respective periods.

Note: Sales covered by the PPRS payment is defined at paragraph 6.7 of the PPRS. The percentage payment applies to these sales, which exclude sales of new products. Sales of new products are included in the calculation of the overall sum to be repaid across all member companies. However, products with a new active substance designation which were introduced after 31 December 2013 are excluded from the sales used to calculate the payment by each company.

Note: Sales covered by the PPRS payment will include sales from submissions that companies have made in accordance with the rules for companies joining the PPRS payment mechanism after September 2014.

TABLE 3 — Statutory scheme sales reports: net sales covered by the statutory scheme payment and resulting payments

Period	Aggregate net sales covered by the statutory scheme payment Column 1	Resulting aggregate statutory scheme payment Column 2
Apr-Dec 2018	£279M	£22M

Table 3 notes

1. Table 3 is derived from audited statutory scheme sales reports for the period during 2018 that companies were covered by the Regulations. It sets out aggregate annual audited information showing net sales covered by the statutory scheme payment and the resulting payments.

General notes

Note 1: The information in all tables is that held on the Department of Health's PPRS operations database at 19 October 2020.

Note 2: All tables are subject to future correction where errors are discovered or where audited data replaces best available data and will be updated at each quarterly publication point to reflect the latest available information. The audit and reconciliation arrangements are set out in paragraphs 6.24-6.30 and 6.37-6.40 of the PPRS. The statutory scheme audit requirements are set out at paragraph 23 of the Regulations.

© Crown copyright 2020

Published to GOV.UK in pdf format only.

Community Care/Medicines and Pharmacy/Medicines Pricing and Supply

www.gov.uk/dhsc

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3

Where we have identified any third-party copyright information you will need to obtain permission from the copyright holders concerned.

